Edesa Biotech is a biopharmaceutical company developing and commercializing innovative therapies for inflammatory and immune-related diseases, focusing on drug candidates with demonstrated human proof-of-concept targeting conditions with large unmet medical needs. The company's pipeline includes EB06, an anti-CXCL10 monoclonal antibody for vitiligo; EB01, a topical treatment for allergic contact dermatitis; and EB05, a first-in-class TLR4-blocking monoclonal antibody for acute respiratory distress syndrome and chronic respiratory conditions. Edesa generates no current product revenue but expects future revenues through direct commercialization of approved products, strategic licensing and partnership arrangements with pharmaceutical companies, and sublicensing to partners in regions where it does not directly market products.